{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:08:30Z","timestamp":1774616910940,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Egypt Heart J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Numerous epidemiological investigations and randomized clinical studies have determined that dyslipidemia is a major contributor to atherosclerotic cardiovascular disease (ASCVD). Consequently, the management of serum cholesterol and low-density lipoprotein levels has become a central objective in the effort to prevent cardiovascular events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>Many guidelines were issued by different organizations and societies to define patient risk and establish important recommendations for management strategies. Newer cholesterol-lowering agents (non-statin drugs) are described, and their use is directed primarily to secondary prevention in patients at very high risk of new ASCVD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The present guidance summarizes the current methods for risk estimation and outlines the most recent data on lipid management in a simple user-friendly format, to improve physician awareness and help implement guidelines in the daily practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s43044-021-00140-1","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T11:12:59Z","timestamp":1614078779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Egyptian practical guidance in lipid management 2020"],"prefix":"10.1186","volume":"73","author":[{"given":"Hesham Salah El Din","family":"Taha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala Mahfouz","family":"Badran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossam","family":"Kandil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabil","family":"Farag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Oraby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdy","family":"El Sharkawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khaled","family":"Shokry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fouad","family":"Fawzy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossam","family":"Mahrous","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Bahgat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Samy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirna Mamdouh","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"140_CR1","doi-asserted-by":"crossref","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal 41(1):111\u2013188","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"140_CR2","unstructured":"Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N et al (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 376(9753):1670\u20131681"},{"key":"140_CR3","doi-asserted-by":"crossref","unstructured":"Michos ED, McEvoy JW, Blumenthal RS (2019) Lipid management for the prevention of atherosclerotic cardiovascular disease. The New England Journal of Medicine 381(16):1557\u20131567","DOI":"10.1056\/NEJMra1806939"},{"key":"140_CR4","doi-asserted-by":"crossref","unstructured":"Reda A, Abdel-Rehim AA, Etman A, Afifi OSA (2014) Centralized pan-Middle East Survey on the under-treatment of hypercholesterolemia: results from the CEPHEUS study in Egypt. Cardiol Ther. 3(1\u20132):27\u201340","DOI":"10.1007\/s40119-014-0031-x"},{"key":"140_CR5","doi-asserted-by":"crossref","unstructured":"Farag ES, Reda A, Farag N, Salama S, Elbahry A, Sanad O et al (2017) The Egyptian cardiovascular risk factors project, phase (II) results: a multicenter observational study of the pattern of risk factor profile in Egyptian patients with acute coronary syndrome. Atherosclerosis. 263:e159","DOI":"10.1016\/j.atherosclerosis.2017.06.505"},{"key":"140_CR6","doi-asserted-by":"crossref","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al (2019) 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology 73(24):3168\u20133209","DOI":"10.1016\/j.jacc.2018.11.002"},{"key":"140_CR7","unstructured":"Mortensen MB, Falk E, Li D, Nasir K, Blaha MJ, Sandfort V et al (2018) Statin Trials, Cardiovascular events, and coronary artery calcification: implications for a trial-based approach to statin therapy in MESA. JACC: Cardiovascular Imaging 11(2P1):221\u2013230"},{"key":"140_CR8","doi-asserted-by":"crossref","unstructured":"Anderson TJ, Gr\u00e9goire J, Pearson GJ, Barry AR, Couture P, Dawes M et al (2016) 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. The Canadian Journal of Cardiology 32(11):1263\u20131282","DOI":"10.1016\/j.cjca.2016.07.510"},{"key":"140_CR9","doi-asserted-by":"crossref","unstructured":"Cooney MT, Dudina AL, Graham IM (2009) Value and limitations of existing scores for the assessment of cardiovascular risk. a review for clinicians. Journal of the American College of Cardiology 54(14):1209\u20131227","DOI":"10.1016\/j.jacc.2009.07.020"},{"key":"140_CR10","doi-asserted-by":"crossref","unstructured":"Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA et al (2015) A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diab Endocrinol 3(5):339\u2013355","DOI":"10.1016\/S2213-8587(15)00081-9"},{"key":"140_CR11","doi-asserted-by":"crossref","unstructured":"Cooney MT, Dudina A, D\u2019Agostino R, Graham IM (2010) Cardiovascular risk-estimation systems in primary prevention: do they differ? do they make a difference? can we see the future? Circulation. 122(3):300\u2013310","DOI":"10.1161\/CIRCULATIONAHA.109.852756"},{"key":"140_CR12","doi-asserted-by":"crossref","unstructured":"Reda A, Elserafy AS, Farag E, Mostafa T, Farag N, Elbahry A et al (2020) Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors. Egypt Hear J. 72(1):23\u201323","DOI":"10.1186\/s43044-020-00058-0"},{"key":"140_CR13","doi-asserted-by":"crossref","unstructured":"Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G et al (2015) National lipid association recommendations for patient-centered management of dyslipidemia: Part 2. Journal of Clinical Lipidology 9(6):S1\u2013S122.e1","DOI":"10.1016\/j.jacl.2015.09.002"},{"key":"140_CR14","doi-asserted-by":"crossref","unstructured":"Reda A, Soliman M, El Kersh A, Abdou W, Mostafa M, Beshay M et al (2019) The pattern of risk-factor profile in Egyptian patients with acute coronary syndrome: phase II of the Egyptian cross-sectional CardioRisk project. Cardiovascular Journal of Africa 30(2):87\u201394","DOI":"10.5830\/CVJA-2018-074"},{"key":"140_CR15","doi-asserted-by":"crossref","unstructured":"Austin MA, Hutter CM, Zimmern RL, Humphries SE (2004) Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. American Journal of Epidemiology 160(5):407\u2013420","DOI":"10.1093\/aje\/kwh236"},{"key":"140_CR16","doi-asserted-by":"crossref","unstructured":"Haase A, Goldberg AC (2012) Identification of people with heterozygous familial hypercholesterolemia. Current Opinion in Lipidology 23(4):282\u2013289","DOI":"10.1097\/MOL.0b013e3283556c33"},{"key":"140_CR17","doi-asserted-by":"crossref","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS et al (2013) Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease. European Heart Journal 34:45","DOI":"10.1093\/eurheartj\/eht273"},{"key":"140_CR18","doi-asserted-by":"crossref","unstructured":"Amarenco P, Labreuche J, Lavall\u00e9e P, Touboul PJ (2004) Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 35(12):2902\u20132909","DOI":"10.1161\/01.STR.0000147965.52712.fa"},{"key":"140_CR19","doi-asserted-by":"crossref","unstructured":"Hirano T (2018) Pathophysiology of diabetic dyslipidemia. Journal of Atherosclerosis and Thrombosis 25(9):771\u2013782","DOI":"10.5551\/jat.RV17023"},{"key":"140_CR20","doi-asserted-by":"crossref","unstructured":"(2018) Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care 41(Suppl 1):S86\u2013S104","DOI":"10.2337\/dc18-S009"},{"key":"140_CR21","doi-asserted-by":"crossref","unstructured":"Mark L, Vallejo-Vaz AJ, Reiber I, Paragh G, Kondapally Seshasai SR, Ray KK (2015) Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: a nationwide survey of 2674 individuals inHungary. Atherosclerosis. 241(1):62\u201368","DOI":"10.1016\/j.atherosclerosis.2015.04.810"},{"key":"140_CR22","doi-asserted-by":"crossref","unstructured":"Nordestgaard M, Humphries J, Ginsberg SE, Masana HN, Descamps L, Wiklund OS, Hegele O, Raal RA, BGC FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG et al (2013) Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal 34:3478\u20133490a","DOI":"10.1093\/eurheartj\/eht273"},{"key":"140_CR23","doi-asserted-by":"crossref","unstructured":"Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJG et al (2015) Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. European Heart Journal 36(9):560\u2013565","DOI":"10.1093\/eurheartj\/ehu058"},{"key":"140_CR24","doi-asserted-by":"crossref","unstructured":"Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM, Chu A et al (2017) Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open 7(9):e016461","DOI":"10.1136\/bmjopen-2017-016461"},{"key":"140_CR25","doi-asserted-by":"crossref","unstructured":"Laufs U, Parhofer KG, Ginsberg HN, Hegele RA (2020) Clinical review on triglycerides. European Heart Journal 41(1):99\u2013109c","DOI":"10.1093\/eurheartj\/ehz785"},{"key":"140_CR26","unstructured":"Hypertriglyceridemia Management According to the 2018 AHA\/ACC Guideline - American College of Cardiology. https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2019\/01\/11\/07\/39\/hypertriglyceridemia-management-according-to-the-2018-aha-acc-guideline"},{"key":"140_CR27","doi-asserted-by":"crossref","unstructured":"Zodda D, Giammona R, Schifilliti S (2018) Treatment strategy for dyslipidemia in cardiovascular disease prevention: focus on old and new drugs. Pharmacy. 6(1):10","DOI":"10.3390\/pharmacy6010010"},{"key":"140_CR28","doi-asserted-by":"crossref","unstructured":"Raghow R (2017) Statins redux: a re-assessment of how statins lower plasma cholesterol. World Journal of Diabetes 8(6):230","DOI":"10.4239\/wjd.v8.i6.230"},{"key":"140_CR29","doi-asserted-by":"crossref","unstructured":"Bays H (2002) Ezetimibe. Expert Opinion on Investigational Drugs 11(11): 6161587\u20131604","DOI":"10.1517\/13543784.11.11.1587"},{"key":"140_CR30","doi-asserted-by":"crossref","unstructured":"Shapiro MD, Tavori H, Fazio S (2018) PCSK9 from basic science discoveries 618 to clinical trials. Circulation Research 122(10):1420\u20131438","DOI":"10.1161\/CIRCRESAHA.118.311227"},{"key":"140_CR31","doi-asserted-by":"crossref","unstructured":"He L, Wickremasingha P, Lee J, Tao B, Mendell-Harary J, Walker J et al (2014) Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. Diabetes Research and Clinical Practice 104(3):401\u2013409","DOI":"10.1016\/j.diabres.2013.12.033"},{"key":"140_CR32","doi-asserted-by":"crossref","unstructured":"Chapman MJ, Redfern JS, McGovern ME, Giral P (2010) Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics 126(3):314\u2013345","DOI":"10.1016\/j.pharmthera.2010.01.008"},{"key":"140_CR33","doi-asserted-by":"crossref","unstructured":"Blom DJ, Raal FJ, Santos RD, Marais AD (2019) Lomitapide and mipomersen\u2014inhibiting microsomal triglyceride transfer protein (MTP) and apoB100 synthesis. Current Atherosclerosis Reports 21(12):48","DOI":"10.1007\/s11883-019-0809-3"}],"container-title":["The Egyptian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-021-00140-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s43044-021-00140-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s43044-021-00140-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T11:24:00Z","timestamp":1614079440000},"score":1,"resource":{"primary":{"URL":"https:\/\/tehj.springeropen.com\/articles\/10.1186\/s43044-021-00140-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["140"],"URL":"https:\/\/doi.org\/10.1186\/s43044-021-00140-1","relation":{},"ISSN":["2090-911X"],"issn-type":[{"value":"2090-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]},"assertion":[{"value":"19 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Hala Mahfouz Badran is a co-author of this study. She has not handled this manuscript to avoid any conflict of interest. The rest of the authors have no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}